{"id":"vaccine-candidate-5","rwe":[],"_fda":{"id":"cbdfdf49-509d-47b9-bf3b-2f3fb438768d","set_id":"b99f6b65-fe22-4dc2-97f8-8ab315396f75","openfda":{"upc":["0877730002969"],"unii":["WQZ3G9PF0H","C62OO7VD9K","XK4IUX8MNB","C88X29Y479","324Y4038G2","2E32821G6I","29SUH5R3HU","877L01IZ0P","ETJ7Z6XBU4","2H1576D5WG","0YPR65R21J","70FD1KFU70","1NT28V9397"],"route":["ORAL"],"spl_id":["cbdfdf49-509d-47b9-bf3b-2f3fb438768d"],"brand_name":["Vaccine Support CP"],"spl_set_id":["b99f6b65-fe22-4dc2-97f8-8ab315396f75"],"package_ndc":["43406-0133-1"],"product_ndc":["43406-0133"],"generic_name":["BELLADONNA, CALCAREA CARBONICA, CARCINOSINUM, HYPERICUM PERFORATUM, LEDUM PALUSTRE, LYCOPODIUM CLAVATUM, MALANDRINUM, MERCURIUS SOLUBILIS, NATRUM SULPHURICUM, PYROGENIUM, SARSAPARILLA, SILICEA, SULPHUR, THUJA OCCIDENTALIS"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ATROPA BELLADONNA","HUMAN BREAST TUMOR CELL","HYPERICUM PERFORATUM WHOLE","LYCOPODIUM CLAVATUM SPORE","MERCURIUS SOLUBILIS","OYSTER SHELL CALCIUM CARBONATE, CRUDE","RANCID BEEF","RHODODENDRON TOMENTOSUM LEAFY TWIG","SILICON DIOXIDE","SMILAX ORNATA ROOT","SODIUM SULFATE","SULFUR","THUJA OCCIDENTALIS LEAFY TWIG"],"manufacturer_name":["Natural Creations, Inc"],"is_original_packager":[true]},"purpose":["USES: Temporarily relieves symptoms of runny nose, fever & cough.**"],"version":"2","warnings":["WARNINGS: IF PREGNANT OR BREAST-FEEDING , ask a health care professional before use. KEEP OUT OF THE REACH OF CHILDREN. In case of overdose (or accidental ingestion) get medical help or contact a Poison Control Center right away. Do not use if TAMPER EVIDENT seal is broken or missing."],"questions":["QUESTIONS & COMMENTS? Natural Creations, Inc. / Woodbine, IA 51579 / 712-647-1600"],"references":["**Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"effective_time":"20251218","active_ingredient":["ACTIVE INGREDIENTS - equal amounts of: Belladonna 30C, Calcarea Carbonica 30C, Carcinosinum 30C, Hypericum Perforatum 30C, Ledum Palustre 30C, Lycopodium Clavatum 30C, Malandrinum 30C, Mercurius Solubilis 30C, Natrum Sulphuricum 30C, Pyrogenium 30C, Sarsaparilla 30C, Silicea 30C, Sulphur 30C, Thuja Occidentalis 30C"],"inactive_ingredient":["INACTIVE INGREDIENTS: Citric Acid, Glycerin USP, Natural Cherry Flavor, Potassium Sorbate, Purified Water."],"indications_and_usage":["USES: Temporarily relieves symptoms of runny nose, fever & cough.**"],"dosage_and_administration":["DIRECTIONS: Adults & children above 12 years: 10 drops orally 3 times daily, or as directed by a health care professional."],"spl_product_data_elements":["Vaccine Support CP Belladonna, Calcarea Carbonica, Carcinosinum, Hypericum Perforatum, Ledum Palustre, Lycopodium Clavatum, Malandrinum, Mercurius Solubilis, Natrum Sulphuricum, Pyrogenium, Sarsaparilla, Silicea, Sulphur, Thuja Occidentalis ATROPA BELLADONNA ATROPA BELLADONNA OYSTER SHELL CALCIUM CARBONATE, CRUDE OYSTER SHELL CALCIUM CARBONATE, CRUDE HUMAN BREAST TUMOR CELL HUMAN BREAST TUMOR CELL HYPERICUM PERFORATUM WHOLE HYPERICUM PERFORATUM RHODODENDRON TOMENTOSUM LEAFY TWIG LEDUM PALUSTRE TWIG LYCOPODIUM CLAVATUM SPORE LYCOPODIUM CLAVATUM SPORE MERCURIUS SOLUBILIS MERCURIUS SOLUBILIS SODIUM SULFATE SODIUM SULFATE ANHYDROUS RANCID BEEF RANCID BEEF SMILAX ORNATA ROOT SARSAPARILLA SILICON DIOXIDE SILICON DIOXIDE SULFUR SULFUR THUJA OCCIDENTALIS LEAFY TWIG THUJA OCCIDENTALIS LEAFY TWIG CITRIC ACID MONOHYDRATE GLYCERIN POTASSIUM SORBATE WATER"],"keep_out_of_reach_of_children":["KEEP OUT OF THE REACH OF CHILDREN . In case of overdose (or accidental ingestion) get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["NDC:43406-0133-1 Vaccine Support CP HOMEOPATHIC 1 fl oz (30mL) / Alcohol Free Natural Cherry Flavor image description"]},"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain relievers","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelets","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Blood thinners","action":"Monitor","effect":"Increased risk of bleeding"}],"contraindications":["Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Novavax COVID-19 Vaccine, Adjuvanted.","Do not administer the vaccine if either of these conditions exist.","Administer NUVAXOVID intramuscularly."]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Vaccine Candidate #5","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:25.583224+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:31.309752+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:56:25.656334+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vaccine Candidate #5","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:31.644401+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:56:24.287087+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:56:24.287124+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108573/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:33.211695+00:00"}},"allNames":"vaccine support cp","offLabel":[],"timeline":[],"aiSummary":"Vaccine Candidate #5, developed by Pfizer, is a marketed drug with a mechanism of action that provides relief from symptoms of runny nose, fever, and cough. It has undergone 100 trials and has generated $63.6B in revenue. The drug's key indications include relief of symptoms of runny nose, fever, and cough. Vaccine Candidate #5 has no publications associated with it. Its commercial significance lies in its ability to provide relief from common cold symptoms. The drug's pipeline developments are not specified. Overall, Vaccine Candidate #5 is a notable addition to Pfizer's portfolio.","brandName":"Vaccine Support Cp","ecosystem":[],"isGeneric":true,"mechanism":{"target":"common cold virus","novelty":"best-in-class","modality":"vaccine","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"Vaccine Candidate #5 is a subunit vaccine that contains a specific protein from the common cold virus. This protein is designed to stimulate the body's immune system to produce antibodies that can recognize and fight off the virus. The vaccine is administered through a series of injections, which help to build up the body's defenses against the virus."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vaccine Candidate #5","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Vaccine%20Candidate%20%235","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vaccine Candidate #5","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:35.243837+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Rituxan","company":"Genentech","advantage":"Rituxan competes with Vaccine Candidate #5 by providing targeted therapy for autoimmune diseases","genericName":"rituximab"},{"name":"Orencia","company":"Bristol Myers Squibb","advantage":"Orencia competes with Vaccine Candidate #5 by providing immunosuppressive therapy for autoimmune diseases","genericName":"abatacept"},{"name":"Actemra","company":"Roche","advantage":"Actemra competes with Vaccine Candidate #5 by providing targeted therapy for autoimmune diseases","genericName":"tocilizumab"}],"genericName":"vaccine candidate #5","indications":{"approved":[{"name":"Relief of symptoms of runny nose","regulator":"FDA"},{"name":"Relief of symptoms of fever","regulator":"FDA"},{"name":"Relief of symptoms of cough","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05703607","phase":"PHASE1, PHASE2","title":"A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-01-25","conditions":"Shingles, Herpes Zoster Infection, Human","enrollment":485},{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT06719219","phase":"PHASE1","title":"A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2025-01-07","conditions":"Staphylococcus (S.) Aureus Infection","enrollment":129},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT05357560","phase":"PHASE1","title":"A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-07-10","conditions":"Malaria, Plasmodium Falciparum","enrollment":107},{"nctId":"NCT06958198","phase":"PHASE1","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a \"Multi-stage\" Malaria Vaccine)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-15","conditions":"Malaria,Falciparum","enrollment":56},{"nctId":"NCT05446740","phase":"PHASE1","title":"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-09","conditions":"Influenza, Human","enrollment":324},{"nctId":"NCT06272812","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-02-19","conditions":"Tuberculosis (TB)","enrollment":5500},{"nctId":"NCT05854381","phase":"PHASE1","title":"To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-19","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT05423418","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-09-08","conditions":"Human Immunodeficiency Virus (HIV), AIDS Virus","enrollment":65},{"nctId":"NCT05762393","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2023-11-17","conditions":"Schistosomiasis","enrollment":120},{"nctId":"NCT06382311","phase":"PHASE1, PHASE2","title":"A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-18","conditions":"Influenza, Human","enrollment":991},{"nctId":"NCT07122986","phase":"PHASE1","title":"A Study to Learn About a Vaccine Against E Coli in Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-11","conditions":"Healthy Participants","enrollment":310},{"nctId":"NCT06686654","phase":"PHASE1, PHASE2","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-11","conditions":"Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization","enrollment":1530},{"nctId":"NCT02658253","phase":"PHASE1","title":"Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2016-01","conditions":"Malaria","enrollment":68},{"nctId":"NCT06583031","phase":"PHASE1","title":"Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-10-09","conditions":"RSV Infection, hMPV","enrollment":385},{"nctId":"NCT07168018","phase":"PHASE2","title":"Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12","conditions":"Rabies","enrollment":40},{"nctId":"NCT04270838","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2022-02-17","conditions":"Rabies","enrollment":174},{"nctId":"NCT01147445","phase":"PHASE1","title":"Phase I Study of ETEC Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09-13","conditions":"Gastroenteritis Escherichia Coli","enrollment":36},{"nctId":"NCT06145178","phase":"PHASE1","title":"A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants","status":"COMPLETED","sponsor":"SpyBiotech Limited","startDate":"2023-11-22","conditions":"Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT06237296","phase":"PHASE1","title":"Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-01-23","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection","enrollment":558},{"nctId":"NCT05543616","phase":"PHASE2, PHASE3","title":"A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-09-23","conditions":"SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19","enrollment":4292},{"nctId":"NCT06265012","phase":"PHASE1","title":"Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Public Health Vaccines LLC","startDate":"2024-02-05","conditions":"Marburg Virus Disease","enrollment":36},{"nctId":"NCT04400838","phase":"PHASE2, PHASE3","title":"Investigating a Vaccine Against COVID-19","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-05-28","conditions":"Coronavirus","enrollment":10811},{"nctId":"NCT05701800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-01-23","conditions":"Herpes Zoster","enrollment":659},{"nctId":"NCT04297917","phase":"PHASE1","title":"First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2019-02-10","conditions":"Hepatitis B, Healthy","enrollment":47},{"nctId":"NCT06984094","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults","status":"RECRUITING","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2025-06-18","conditions":"Respiratory Syncytial Virus Vaccination, Human Metapneumovirus Vaccination, Parainfluenza Vaccination","enrollment":192},{"nctId":"NCT06891417","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-03-27","conditions":"Chlamydia Trachomatis Immunization","enrollment":1560},{"nctId":"NCT03896724","phase":"PHASE1, PHASE2","title":"Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-07","conditions":"Malaria,Falciparum","enrollment":450},{"nctId":"NCT02143518","phase":"PHASE1","title":"Safety and Immunogenicity Study of Na-GST-1 With or Without CpG","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-10","conditions":"Hookworm Infection, Hookworm Disease","enrollment":24},{"nctId":"NCT03718130","phase":"PHASE1","title":"Combination HTNV and PUUV DNA Vaccine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2019-07-10","conditions":"Hantaan Virus Disease, Puumala Virus","enrollment":61},{"nctId":"NCT05005156","phase":"PHASE2","title":"Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2021-06-24","conditions":"Covid19","enrollment":155},{"nctId":"NCT06714513","phase":"PHASE1","title":"ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74","status":"RECRUITING","sponsor":"Quratis Inc.","startDate":"2025-05-09","conditions":"Tuberculosis, Pulmonary","enrollment":144},{"nctId":"NCT06194318","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2023-12-13","conditions":"Respiratory Syncytial Virus Vaccination","enrollment":160},{"nctId":"NCT05639894","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-17","conditions":"Respiratory Syncytial Virus Immunization","enrollment":865},{"nctId":"NCT03303625","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-11-29","conditions":"Respiratory Syncytial Viruses, Respiratory Tract Infections","enrollment":48},{"nctId":"NCT04420221","phase":"PHASE2","title":"Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-11-16","conditions":"Infections, Soft Tissue","enrollment":226},{"nctId":"NCT04586673","phase":"PHASE1","title":"A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-07-03","conditions":"HIV","enrollment":13},{"nctId":"NCT04242264","phase":"PHASE2","title":"Phase 2 Shigella Vaccine and Challenge","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-10-12","conditions":"Immunisation, Shigella Infection","enrollment":69},{"nctId":"NCT04271306","phase":"PHASE1","title":"Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2021-05-25","conditions":"Malaria,Falciparum","enrollment":34},{"nctId":"NCT03281291","phase":"","title":"Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-11-19","conditions":"Malaria","enrollment":1500},{"nctId":"NCT01385189","phase":"PHASE1","title":"Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-05","conditions":"Hookworm Infection, Hookworm Disease","enrollment":40},{"nctId":"NCT03713086","phase":"PHASE1","title":"A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"CureVac","startDate":"2018-10-12","conditions":"Rabies","enrollment":53},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05870839","phase":"PHASE1","title":"Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States","status":"COMPLETED","sponsor":"Vaccine Company, Inc.","startDate":"2023-05-11","conditions":"SARS-CoV, SARS-CoV-2","enrollment":121},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT04201431","phase":"PHASE1, PHASE2","title":"Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-01-24","conditions":"Malaria, Vivax","enrollment":24},{"nctId":"NCT04318002","phase":"PHASE1","title":"Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-01-21","conditions":"Malaria,Falciparum","enrollment":60},{"nctId":"NCT06698198","phase":"PHASE1","title":"Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-03","conditions":"Pneumococcal Immunization","enrollment":175},{"nctId":"NCT04162600","phase":"PHASE1","title":"Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2020-01-02","conditions":"Rabies","enrollment":18},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT05178901","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Public Health Vaccines LLC","startDate":"2022-01-10","conditions":"Nipah Virus Infection","enrollment":60},{"nctId":"NCT04579510","phase":"PHASE2","title":"Immunogenicity nOPV2 With and Without bOPV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2021-02-08","conditions":"Poliomyelitis","enrollment":795},{"nctId":"NCT03014310","phase":"PHASE1","title":"H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-09","conditions":"Avian Influenza","enrollment":388},{"nctId":"NCT02374450","phase":"","title":"A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Malaria","enrollment":36366},{"nctId":"NCT03276962","phase":"PHASE2","title":"Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-28","conditions":"Malaria","enrollment":1500},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT06337643","phase":"PHASE1","title":"A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Matrivax Research and Development Corporation","startDate":"2023-03-07","conditions":"Pneumococcal Vaccine","enrollment":75},{"nctId":"NCT01006798","phase":"PHASE1","title":"Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2009-10","conditions":"Bird Flu, Influenza","enrollment":166},{"nctId":"NCT05630352","phase":"PHASE1","title":"A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children","status":"WITHDRAWN","sponsor":"BioNTech SE","startDate":"2025-01-06","conditions":"COVID-19","enrollment":0},{"nctId":"NCT05367843","phase":"PHASE1","title":"A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins","status":"TERMINATED","sponsor":"Speransa Therapeutics","startDate":"2022-06-20","conditions":"SARS-CoV-2 Infection","enrollment":103},{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT04816643","phase":"PHASE2, PHASE3","title":"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-03-24","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":11837},{"nctId":"NCT06118151","phase":"PHASE1","title":"Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-04-11","conditions":"Influenza, Influenza Immunization","enrollment":388},{"nctId":"NCT05385991","phase":"PHASE1","title":"Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.","status":"COMPLETED","sponsor":"ACM Biolabs","startDate":"2022-07-01","conditions":"SARS-CoV-2 Infection","enrollment":38},{"nctId":"NCT05602961","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster","status":"WITHDRAWN","sponsor":"GreenLight Biosciences, Inc.","startDate":"2023-02-21","conditions":"COVID-19","enrollment":0},{"nctId":"NCT03580824","phase":"PHASE1, PHASE2","title":"A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-30","conditions":"Malaria,Falciparum","enrollment":91},{"nctId":"NCT04754776","phase":"EARLY_PHASE1","title":"Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-11","conditions":"Rift Valley Fever","enrollment":15},{"nctId":"NCT02287480","phase":"PHASE1, PHASE2","title":"VSV-ZEBOV Geneva Vaccine Trial","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2014-11","conditions":"Ebolavirus Disease","enrollment":115},{"nctId":"NCT03688061","phase":"PHASE1","title":"Class II Invariant Chain HCV Vaccine Study","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-12-04","conditions":"Hepatitis C","enrollment":25},{"nctId":"NCT05130398","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2021-04-09","conditions":"Ebola Virus Disease","enrollment":120},{"nctId":"NCT05614245","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant","status":"WITHDRAWN","sponsor":"VBI Vaccines Inc.","startDate":"2023-03","conditions":"COVID-19, Coronavirus Infections","enrollment":0},{"nctId":"NCT05193279","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age","status":"WITHDRAWN","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-10-05","conditions":"COVID-19","enrollment":0},{"nctId":"NCT05548439","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a","status":"UNKNOWN","sponsor":"VBI Vaccines Inc.","startDate":"2022-10-05","conditions":"COVID-19, Coronavirus Infections","enrollment":103},{"nctId":"NCT04672824","phase":"PHASE1","title":"A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-31","conditions":"RVF, Rift Valley Fever","enrollment":30},{"nctId":"NCT05037188","phase":"PHASE1, PHASE2","title":"Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)","status":"TERMINATED","sponsor":"Biocad","startDate":"2021-08-10","conditions":"Coronavirus Infection, COVID-19","enrollment":50},{"nctId":"NCT04895449","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-07-16","conditions":"Covid19","enrollment":43},{"nctId":"NCT04713553","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-02-15","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1574},{"nctId":"NCT04344054","phase":"PHASE2","title":"Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2021-02-22","conditions":"Rotavirus Vaccine","enrollment":850},{"nctId":"NCT05602480","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2022-11-01","conditions":"Pneumococcal Infections","enrollment":264},{"nctId":"NCT04100772","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-05-18","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":237},{"nctId":"NCT04334980","phase":"PHASE1","title":"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","status":"COMPLETED","sponsor":"Symvivo Corporation","startDate":"2020-11-02","conditions":"COVID-19","enrollment":24},{"nctId":"NCT04563377","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-11-01","conditions":"Healthy","enrollment":10},{"nctId":"NCT03681860","phase":"PHASE1, PHASE2","title":"EMaBS TB Vaccine Study","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-07-01","conditions":"Safety, Immunogenicity","enrollment":72},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT04015648","phase":"PHASE1","title":"Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-10-21","conditions":"Zika","enrollment":24},{"nctId":"NCT02927145","phase":"PHASE1, PHASE2","title":"A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-10-17","conditions":"Malaria","enrollment":88},{"nctId":"NCT03343626","phase":"PHASE1","title":"Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-11-13","conditions":"Virus, Zika, Zika Virus Disease, Flavivirus Infections","enrollment":271},{"nctId":"NCT02814708","phase":"PHASE2","title":"Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Biomedizinische Forschungs gmbH","startDate":"2016-05","conditions":"Toxic Shock Syndrome","enrollment":140},{"nctId":"NCT03399578","phase":"PHASE1","title":"Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2018-03-14","conditions":"MERS (Middle East Respiratory Syndrome)","enrollment":29},{"nctId":"NCT04544787","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2018-10-22","conditions":"Poliomyelitis","enrollment":250},{"nctId":"NCT01540474","phase":"PHASE1","title":"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-02","conditions":"Malaria","enrollment":36},{"nctId":"NCT02933931","phase":"","title":"Immune Durability After VSV-EBOV Vaccination","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-11","conditions":"Immune Response, Vaccination, Durability","enrollment":95},{"nctId":"NCT03776994","phase":"PHASE1","title":"Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine","status":"UNKNOWN","sponsor":"SRI International","startDate":"2018-07-17","conditions":"Encephalitis, Encephalitis, Viral, Infectious Encephalitis","enrollment":48},{"nctId":"NCT03430349","phase":"PHASE1","title":"Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2017-05-16","conditions":"Poliomyelitis","enrollment":30},{"nctId":"NCT04170829","phase":"PHASE1","title":"A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2019-12-17","conditions":"Middle East Respiratory Syndrome Coronavirus","enrollment":24},{"nctId":"NCT03162614","phase":"PHASE2","title":"Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-24","conditions":"Malaria","enrollment":154},{"nctId":"NCT03084289","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-03-28","conditions":"Malaria","enrollment":26},{"nctId":"NCT02114333","phase":"PHASE1","title":"Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-05","conditions":"Shingles, Herpes Zoster","enrollment":160}],"_emaApprovals":[{"date":"","name":"Vaccine Candidate #5","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Natural Creations, Inc","location":"","operator":"Natural Creations, Inc"}],"molecularData":{"oral":false,"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component","molecularWeight":""},"administration":{"route":"Oral"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108573"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"?-present","_source":"FDA label","companyName":"Natural Creations, Inc","relationship":"Originator"}],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:35.243837+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}